Summary
Panic disorder like other neuropsychiatric disorders is believed to be caused by multiple psychosocial and biological factors. Several lines of evidence point to a role for the peptide neurotransmitter cholecystokinin in the pathogenesis of panic disorder. We therefore determined the allele and genotype frequencies of a single nucleotide polymorphism in the CCK gene (−36C > T) and one CT repeat polymorphism in the CCK-B-receptor gene in a German panic disorder sample (n = 115 for CCK gene polymorphism, n = 111 for CCK-B-receptor polymorphism) and compared them with gender and age matched controls . The length of the polymorphic CT repeat alleles varies between 146bp and 180bp. We first analysed the results by a permutation test which provided evidence for heterogeneity between patients and controls (p = 0.002). We then analysed the data as a di-allelic polymorphism with a short (146-162 bp) and a long (l64-180bp) allele and as a tetra-allelic polymorphism with 4 alleles (146–154 bp, 156–162 bp, 164–170 bp, 172–180 bp). In the di-allelic analysis as well as in the tetra-allelic analysis there was an excess of the longer allele (p = 0.001) or the two longer alleles (p = 0.041) respectively in patients with panic disorder. No difference between groups was observed for the − 36C > T polymorphism. Our findings are consistent with the notion that genetic variation in the CCK neurotransmitter system contributes to the pathogenesis of panic disorder.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bradweijn J, Koszycki D, Shriqui C (1991) Enhanced sensitivity to cholecystokinin-tetrapeptide in panic disorder: clinic al and behavioural findings. Arch Gen Psychiatry 48: 603–610
Deckert J, Catalano M, Syagailo YV, Bosi M, Okladnova O, Di Bella D, Nothen MM, Maffei P, Franke P, Fritze J, Maier W, Propping P, Beckrnann H, Bellodi L, Lesch KP (1999) Excess of high activity monoamine oxidase A gene promoter allele s in female patients with panic disorder. Hum Mol Genet 8: 621–624
Ebihara M, Ohba H, Hattoro E, Yamada K, Yoshikawa T (2003) Transcriptional activities of cholecystokinin promoter haplotypes and their relevance to panic disorder susceptibility. Am J Med Genet 118B: 32–35
Gratacos M, Nadal M, Martin-Santos R, Pujana MA, Gago J, Peral B, Armengol L, Ponsa I, Miro R Bulbena A, Estivill X (2001) A polymorphic genomic duplication on human chromosome 15 is a susceptibility factor for panic and phobic disorders. Cell 106: 367–379
Hamilton SP, Slager SL, Helleby L, Heiman GA, Klein DF, Hodge SE, Weissman MM, Fyer AJ, Knowles JA (2001) No association or linkage between polymorphisms in the genes encoding cholezystokinin and the cholezystokinin B receptor and panic disorder. Mol Psychiatry 6: 59–65
Hamilton SP, Slager SL, Heiman GA, Deng Z, Haghighi F, Klein DF, Hodge SE, Weissman MM, Fyer AJ, Knowles JA (2002) Evidence for a susceptibility locus for panic disorder near the catechol-O-methyltransferase gene on chromosome 22. Biol Psychiatry 51: 591–601
Hamilton SP, Fyer AJ, Durner M, Heiman GA, Baisre de Leon A, Hodge SE, Knowles JA, Weissman MM (2003) Further genetic evidence for a panic disorder syndrome mapping to chromosome 13q. PNAS USA 100: 2550–2555
Hattori E, Ebihara M, Yamada K, Ohba H, Shibuya H, Yoshikawa T (2001) Identification of a short tandem repeat stretch in the 5’-upstream region of the cholecystokinin gene, and its association with panic disorder but not with schizophrenia. Mol Psychiatry 6: 465–470
Hettema JM, Neale MC, Kendler KS (2001) A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 158: 1568–1578
Jenck F, Martin JR, Moreau J-L (1996) Behavioral effects of CCKB receptor ligands in a validated simulation of panic anxiety in rats. Eur Neuropsychopharmacol 4: 291–298
Kennedy JL, Bradwejn J, Koszycki D, King N, Crowe R, Vincent J, Fourie O (1999) Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry 4: 284–285
Maier W, Lichtermann D, Minges J, Oehrlein A, Franke P (1993) A controlled family study in panic disorder. J Psychiatr Res 27: 79–87
Mannuzza S, Fyer AJ, Klein DF, Endicott J (1986) Schedule for Affective Disorders and Schizophrenia-Lifetime Version modified for the study of anxiety disorders (SADS-LA): rationale and conceptual development. J Psychiatr Res 20: 317–325
Moran TH, Robinson PH, Goldrich MS, McHugh PR (1986) Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res 362: 175–I79
Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R Regier DA, Sartorius N, Towle LH (1988) The Composite International Diagnostic Interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 45: 1069–1077
Sand PG, Schlurmann K, Luckhaus C, Gotz M, Stober G, Lesch KP, Riederer P, Franke P, Maier W Nothen M, Propping P, Fritze J, Deckert J (2002) Estrogen receptor 1 gene (ESR 1) variants in panic disorder (Letter). Am J Med Genet 114: 426–428
Sasieni PD (1997) From genotypes to genes: doubling the sample size. Biometrics 53: 1253–1261
Song I, Brown DR, Wiltshire RN, Gantz I, Trent JM, Yamada T (1993) The human gastrin / cholecystokinin type B receptor gene: alternat ive splice donor site in exon 4 generates two variant mRNAs. Proc Natl Acad Sci USA 90: 9085–9089
Takahashi Y, Fukushige S, Murotsu T, Matsubara K (1986) Structure of the human cholecystokinin gene and its chromosomal location. Gene 50: 353–366
Thorgeirsson TE, Oskarsson H, Desnica N, Kostic JP, Stefansson JG, Kolbeinsson H, Lindal E, Gagunashvili N, Frigge ML, Kong A, Stefansson K, Gulcher JR (2003) Anxiety with panic disorder linked to chromosome 9q in Iceland. Am J Hum Genet 72: 1221–1230
Vancerhaeghen J-J, Signeau JC, Gepts W (1975) New peptide in the vertebrate CNS interacting with antigastrin antibodies. Nature 257: 604–605
van Megen HJGM, Westenberg HGM, den Boer JA, Slaap B, van Es-Radhakishun F, Pande A (1997) The cholecystokinin-B-receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacol 129(3): 243–248
Vieland VJ, Goodman DW, Chapman T, Fyer AJ (1996) New segregation analysis of panic disorder. Am J Med Genet 67: 147–153
Wang Z, Valdes J, Russell N, Zoega T, Crowe R (1998) Possible association of a cholecystokinin promotor polymorphism with panic disorder. Am J Med Genet 81: 228–234
Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, Joyce PR, Karam EG Lee CK, Lellouch J, Lepine JP, Newman SC, Oakley-Browne MA, Rubio-Stipec M, Wells JE, Wickramaratne PJ, Wittchen HU, Yeh EK (1997) The cross-national epidemiology of panic disorder. Arch Gen Psychiatry 54: 305–309
Wittchen HU, Garczynski E, Pfister H (1997) Composite International Diagnostic Interview according to ICD-IOand DSM-IY. Hogrefe, Gottingen
Yamada K, Hattori E, Shimizu M, Sugaya A, Shibuya H, Yoshikawa T (2001) Association studies of the cholezystokinin B recept or and A2a adenosine receptor genes in panic disorder. J Neural Transm 108: 837–848
Zhao JH, Curtis S, Sham PC (2000) Model-free analysis and permutation tests for allelic associations. Hum Hered 50: 133–139
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Wien
About this chapter
Cite this chapter
Hösing, V.G. et al. (2004). Cholecystokinin- and cholecystokinin-B-receptor gene polymorphisms in panic disorder. In: Müller, T., Riederer, P. (eds) Focus on Extrapyramidal Dysfunction. Journal of Neural Transmission. Supplementa, vol 68. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0579-5_17
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0579-5_17
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-21114-4
Online ISBN: 978-3-7091-0579-5
eBook Packages: Springer Book Archive